MIRA Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
MIRA Pharmaceuticals, Inc. (MIRA) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 171.78% as of 2026-06-12, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-12
- 2026-06-12: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 171.78%.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month 209.95%.
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month 116.64%.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month 87.70%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month |
|---|---|---|---|
| 2026-06-12 | 171.78% 10-Q · filed 2026-08-12 | ||
| 2025-09-30 | 209.95% 10-Q · filed 2025-11-13 | ||
| 2023-09-30 | 116.64% 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | 87.70% 10-Q · filed 2023-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |